MarketInOut Stock Screener Log In | Sign Up

Aldeyra Therapeutics Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/17/2026 16:00
Aldeyra Therapeutics Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization38.86 mln
Float58.10 mln
Earnings Date11/04/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

96 / 100
Top performer

Debt / Equity

0.01
Debt-free

ROE

-50.37
Deeply negative

ROA

-33.04
Deeply negative

Business Description

Aldeyra Therapeutics is a Massachusetts-based biotechnology company focused on developing treatments for immune-related conditions. Its most advanced drug candidates include reproxalap, currently in late-stage trials for dry eye disease and eye allergies, and ADX-2191, which targets rare eye cancers and retinal disorders. The company is also testing an oral medication called ADX-629 for conditions ranging from asthma and psoriasis to COVID-19. Founded in 2004, Aldeyra continues to build a broader pipeline of experimental therapies aimed at addressing a wide range of inflammatory diseases.

Key Fundamentals

EPS-0.31
ROE-50.37
ROIC-106
ROA-33.04
Interest Cover-21.39
EBITDA, mln-21.37
EV / EBITDA0.37
EV / EBIT0.36

Quote Details

Last 0.6939
Change 0.0243 (3.63%)
Open 0.6721
Volume 741,830
Turnover 514,756
Average Volume 813,898

Financial Ratios

Leverage Ratio1.23
Current Ratio4.84
Price / Book0.98
Price / Tangible Book0.98
Debt / Equity0.01

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio1.84
Short % of Float5.41

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 10.3% 97 / 100   
1 Month 4.33% 87 / 100   
2 Months -54.35% 11 / 100   
6 Months -54.94% 13 / 100   
1 Year -86.26% 7 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog